ROS in Cancer: The Burning Question

Trends in Molecular Medicine

Volumn 23, Issue 5, 2017, Pages 411-429

  Chio, Iok In Christine ^a,b   Tuveson, David A ^a,b  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b Lustgarten Foundation Pancreatic Cancer Laboratory at Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CYSTEINE; FREE RADICAL; REACTIVE OXYGEN METABOLITE;

CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL MIGRATION; HUMAN; MALIGNANT NEOPLASM; METABOLISM; METASTASIS; MITOCHONDRIAL RESPIRATION; MITOGENESIS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 85017530537     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.03.004     Document Type: Review

References (215)

1. 1 Cross, C.E., et al. Oxygen radicals and human disease. Ann. Intern. Med. 107 (1987), 526–545.
2. 2 Andersen, J.K., Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10:Suppl (2004), S18–S25.
3. 3 Mugge, A., The role of reactive oxygen species in atherosclerosis. Z. Kardiol. 87 (1998), 851–864.
4. 4 Paravicini, T.M., Touyz, R.M., Redox signaling in hypertension. Cardiovasc. Res. 71 (2006), 247–258.
5. 5 Haigis, M.C., Yankner, B.A., The aging stress response. Mol. Cell 40 (2010), 333–344.
6. 6 Poole, L.B., Protein sulfenic acids in redox signaling. Ann. Rev. Pharmacol. Toxicol. 44 (2004), 325–347.
7. 7 Fridovich, I., Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J. Biol. Chem. 272 (1997), 18515–18517.
8. 8 Radi, R., Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266 (1991), 4244–4250.
9. 9 Inarrea, P., Redox activation of mitochondrial intermembrane space Cu,Zn-superoxide dismutase. Biochem. J. 387 (2005), 203–209.
10. 10 Murphy, M.P., How mitochondria produce reactive oxygen species. Biochem. J. 417 (2009), 1–13.
11. 11 Han, D., Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J. Biol. Chem. 278 (2003), 5557–5563.
12. 12 Muller, F.L., Complex III releases superoxide to both sides of the inner mitochondrial membrane. J. Biol. Chem. 279 (2004), 49064–49073.
13. 13 Sturtz, L.A., et al. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J. Biol. Chem. 276 (2001), 38084–38089.
14. 14 Stralin, P., The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler. Thromb. Vasc. Biol. 15 (1995), 2032–2036.
15. 15 Marklund, S.L., Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. Biochem. J. 222 (1984), 649–655.
16. 16 Bedard, K., Krause, K.H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87 (2007), 245–313.
17. 17 Fisher, A.B., Redox signaling across cell membranes. Antioxid. Redox Signal. 11 (2009), 1349–1356.
18. 18 Lloyd, R.V., The origin of the hydroxyl radical oxygen in the Fenton reaction. Free Radic. Biol. Med. 22 (1997), 885–888.
19. 19 Dizdaroglu, M., Jaruga, P., Mechanisms of free radical-induced damage to DNA. Free Radic. Res. 46 (2012), 382–419.
20. 20 Chen, Y., et al. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 16 (2009), 1040–1052.
21. 21 Rhee, S.G., Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem. 287 (2012), 4403–4410.
22. 22 Berndt, C., et al. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 292 (2007), H1227–H1236.
23. 23 Biteau, B., et al. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425 (2003), 980–984.
24. 24 Woo, H.A., Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science 300 (2003), 653–656.
25. 25 Couto, N., et al. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic. Biol. Med. 95 (2016), 27–42.
26. 26 Mannervik, B., The enzymes of glutathione metabolism: an overview. Biochem. Soc. Trans. 15 (1987), 717–718.
27. 27 Holmgren, A., Lu, J., Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun. 396 (2010), 120–124.
28. +-specific isocitrate dehydrogenases in Saccharomyces cerevisiae. J. Biol. Chem. 273 (1998), 31486–31493.
29. 29 Locasale, J.W., Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13 (2013), 572–583.
30. 30 Fan, J., Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510 (2014), 298–302.
31. 31 Lewis, C.A., Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55 (2014), 253–263.
32. 32 Higgins, L.G., Hayes, J.D., The cap‘n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. Chem. Biol. Interact. 192 (2011), 37–45.
33. 33 Kapeta, S., Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J. Biol. Chem. 285 (2010), 8171–8184.
34. 34 Kwak, M.K., Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell Biol. 23 (2003), 8786–8794.
35. 35 Meakin, P.J., Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol. Cell Biol. 34 (2014), 3305–3320.
36. 36 Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39 (2014), 199–218.
37. 37 DeNicola, G.M., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
38. 38 Chio, I.I., NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166 (2016), 963–976.
39. 39 Ishii, T., Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275 (2000), 16023–16029.
40. 40 Itoh, K., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13 (1999), 76–86.
41. 41 Kobayashi, M., Yamamoto, M., Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 46 (2006), 113–140.
42. 42 Zhang, D.D., Hannink, M., Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol. 23 (2003), 8137–8151.
43. 2 involves KEAP1 disulfide formation. J. Biol. Chem. 285 (2010), 8463–8471.
44. 44 Rada, P., SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell Biol. 31 (2011), 1121–1133.
45. 45 Chowdhry, S., Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32 (2013), 3765–3781.
46. 46 Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191.
47. 47 Wu, K.C., Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol. Sci. 123 (2011), 590–600.
48. 48 DeNicola, G.M., NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47 (2015), 1475–1481.
49. 49 Mitsuishi, Y., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
50. 50 Budanov, A.V., et al. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304 (2004), 596–600.
51. 51 Kruiswijk, F., p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16 (2015), 393–405.
52. 52 Bensaad, K., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006), 107–120.
53. 53 Cheung, E.C., et al. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 20491–20496.
54. 54 Yin, L., Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood 119 (2012), 810–816.
55. 55 Cameron, E., Pauling, L., Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. U. S. A. 73 (1976), 3685–3689.
56. 56 Cameron, E., Pauling, L., Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. U. S. A. 75 (1978), 4538–4542.
57. 57 Szatrowski, T.P., Nathan, C.F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51 (1991), 794–798.
58. 58 Ames, B.N., et al. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 7915–7922.
59. 59 Sabharwal, S.S., Schumacker, P.T., Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel?. Nat. Rev. Cancer 14 (2014), 709–721.
60. 60 Sayin, V.I., Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med., 6, 2014, 221ra215.
61. 61 Piskounova, E., Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527 (2015), 186–191.
62. 62 Le Gal, K., Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med., 7, 2015, 308re308.
63. 63 Deghan Manshadi, S., Folic acid supplementation promotes mammary tumor progression in a rat model. PLoS One, 9, 2014, e84635.
64. 64 Ebbing, M., Cancer incidence and mortality after treatment with folic acid and vitamin B12. J. Am. Med. Assoc. 302 (2009), 2119–2126.
65. 65 Fortmann, S.P., et al. Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. 2013, Agency for Healthcare Research and Quality.
66. 66 van Zandwijk, N., et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 92 (2000), 977–986.
67. 67 Goodman, G.E., et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J. Natl. Cancer Inst. 96 (2004), 1743–1750.
68. 68 Klein, E.A., Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Am. Med. Assoc. 306 (2011), 1549–1556.
69. 69 Safford, S.E., Suppression of fibrosarcoma metastasis by elevated expression of manganese superoxide dismutase. Cancer Res. 54 (1994), 4261–4265.
70. 70 St Clair, D.K., Suppression of radiation-induced neoplastic transformation by overexpression of mitochondrial superoxide dismutase. Mol. Carcinog. 6 (1992), 238–242.
71. 71 Irani, K., Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275 (1997), 1649–1652.
72. 72 Ogrunc, M., Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ. 21 (2014), 998–1012.
73. 73 Sohn, J., Rudolph, J., Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction. Biochemistry 42 (2003), 10060–10070.
74. 74 Yang, J.Q., Superoxide generation in v-Ha-ras-transduced human keratinocyte HaCaT cells. Mol. Carcinog. 26 (1999), 180–188.
75. 75 Sablina, A.A., The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005), 1306–1313.
76. 76 Li, T., Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149 (2012), 1269–1283.
77. 77 Greer, E.L., Brunet, A., FOXO transcription factors in ageing and cancer. Acta Physiol. 192 (2008), 19–28.
78. 78 Cao, L., et al. Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis 28 (2007), 1401–1407.
79. 79 Gorrini, C., BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 210 (2013), 1529–1544.
80. 80 Shibutani, S., Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349 (1991), 431–434.
81. 81 Chiang, A.C., Massague, J., Molecular basis of metastasis. N. Engl. J. Med. 359 (2008), 2814–2823.
82. 82 Diaz, B., et al. Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal., 2, 2009, ra53.
83. 83 Giannoni, E., Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 28 (2009), 2074–2086.
84. 84 Weinberg, F., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 8788–8793.
85. 85 Ishikawa, K., ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320 (2008), 661–664.
86. 86 Teoh-Fitzgerald, M.L., Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. Oncogene 33 (2014), 358–368.
87. 87 Porporato, P.E., A mitochondrial switch promotes tumor metastasis. Cell Rep. 8 (2014), 754–766.
88. 2. J. Biol. Chem. 277 (2002), 20336–20342.
89. 89 Salmeen, A., Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423 (2003), 769–773.
90. 90 Son, Y., et al. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?. J. Signal Transduct., 2011, 2011, 792639.
91. 91 Liu, P., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8 (2009), 627–644.
92. 92 Roberts, P.J., Der, C.J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007), 3291–3310.
93. 93 Neumann, C.A., Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424 (2003), 561–565.
94. 94 No, J.H., Targeting nrf2 signaling to combat chemoresistance. J. Cancer Prev. 19 (2014), 111–117.
95. 95 Zhang, P., Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9 (2010), 336–346.
96. 96 Chen, R.S., et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 28 (2009), 599–609.
97. 97 Huang, Y., Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65 (2005), 7446–7454.
98. 98 Lo, M., et al. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol. 215 (2008), 593–602.
99. 99 Guo, W., Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 312 (2011), 55–61.
100. 100 Gout, P.W., et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15 (2001), 1633–1640.
101. 101 Chung, W.J., et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 25 (2005), 7101–7110.
102. 102 Doxsee, D.W., et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67 (2007), 162–171.
103. 103 Narang, V.S., Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 23 (2003), 4571–4579.
104. 104 Jiang, L., Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (2015), 57–62.
105. 105 Harris, I.S., Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222.
106. 106 Lui, V.W., Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene 30 (2011), 1127–1134.
107. 107 Wanka, C., Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J. Biol. Chem. 287 (2012), 33436–33446.
108. 108 Cheung, E.C., et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev. Cell 25 (2013), 463–477.
109. 109 Schafer, Z.T., Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 (2009), 109–113.
110. 110 Debnath, J., Brugge, J.S., Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5 (2005), 675–688.
111. 111 Debnath, J., The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111 (2002), 29–40.
112. 112 Chen, E.I., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67 (2007), 1472–1486.
113. 113 Dey, S., ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Invest. 125 (2015), 2592–2608.
114. 114 Dong, C., et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23 (2013), 316–331.
115. 115 Kamarajugadda, S., Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis. Cell Death Dis., 4, 2013, e504.
116. 116 Lu, X., Metabolomic changes accompanying transformation and acquisition of metastatic potential in a syngeneic mouse mammary tumor model. J. Biol. Chem. 285 (2010), 9317–9321.
117. 117 Qu, Y., et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kappaB signaling. J. Clin. Invest. 121 (2011), 212–225.
118. 118 Jiang, L., Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532 (2016), 255–258.
119. 119 Ichijo, H., Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275 (1997), 90–94.
120. 120 Moon, D.O., Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett. 288 (2010), 204–213.
121. 121 Saitoh, M., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998), 2596–2606.
122. 122 Thornton, T.M., Rincon, M., Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int. J. Biol. Sci. 5 (2009), 44–51.
123. 123 Tobiume, K., ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2 (2001), 222–228.
124. 124 Wagner, E.F., Nebreda, A.R., Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9 (2009), 537–549.
125. 125 Wang, L., The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J. Immunol. 180 (2008), 3072–3080.
126. 126 Tan, P.L., Differential thiol oxidation of the signaling proteins Akt, PTEN or PP2A determines whether Akt phosphorylation is enhanced or inhibited by oxidative stress in C2C12 myotubes derived from skeletal muscle. Int. J. Biochem. Cell Biol. 62 (2015), 72–79.
127. 127 Aruoma, O.I., et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6 (1989), 593–597.
128. 128 White, A.C., Reduction of endothelial cell related TGFbeta activity by thiols. Endothelium 6 (1999), 231–239.
129. 129 Liu, M., Antioxidant action via p53-mediated apoptosis. Cancer Res. 58 (1998), 1723–1729.
130. 130 Wang, X.J., Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 66 (2006), 10983–10994.
131. 131 Cairns, R.A., et al. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
132. 132 Ye, J., Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4 (2014), 1406–1417.
133. 133 Brunelle, J.K., et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1 (2005), 409–414.
134. 134 Guzy, R.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1 (2005), 401–408.
135. 135 Mansfield, K.D., Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 1 (2005), 393–399.
136. 136 Pan, Y., Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol. Cell Biol. 27 (2007), 912–925.
137. 137 Chua, Y.L., et al. Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. J. Biol. Chem. 285 (2010), 31277–31284.
138. 138 Orr, A.L., Suppressors of superoxide production from mitochondrial complex III. Nat. Chem. Biol. 11 (2015), 834–836.
139. 139 Abramov, A.Y., et al. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J. Neurosci. 27 (2007), 1129–1138.
140. 140 Adam-Vizi, V., Chinopoulos, C., Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27 (2006), 639–645.
141. 141 Giulivi, C., Hydroxyl radical generation during mitochondrial electron transfer and the formation of 8-hydroxydesoxyguanosine in mitochondrial DNA. Arch. Biochem. Biophys. 316 (1995), 909–916.
142. 142 Heales, S.J., Nitric oxide, mitochondria and neurological disease. Biochim. Biophys. Acta 1410 (1999), 215–228.
143. 143 Choi, M.H., Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435 (2005), 347–353.
144. 2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol. Cell Biol. 26 (2006), 140–154.
145. 145 Ushio-Fukai, M., Localizing NADPH oxidase-derived ROS. Sci. STKE, 2006, 2006, re8.
146. 146 Vilhardt, F., van Deurs, B., The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. EMBO J. 23 (2004), 739–748.
147. 147 Kwon, J., et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 16419–16424.
148. 148 Dixon, S.J., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
149. 149 Kim, Y.S., TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell 26 (2007), 675–687.
150. 150 Hsieh, C.C., Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells. Cardiovasc. Res. 49 (2001), 135–145.
151. 151 Cominacini, L., et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275 (2000), 12633–12638.
152. 152 Cheung, E.C., et al. Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes Dev. 30 (2016), 52–63.
153. 153 Chandel, N.S., Tuveson, D.A., The promise and perils of antioxidants for cancer patients. N. Engl. J. Med. 371 (2014), 177–178.
154. 154 Halliwell, B., Gutteridge, J.M., Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246 (1986), 501–514.
155. 155 Winterbourn, C.C., Metodiewa, D., Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic. Biol. Med. 27 (1999), 322–328.
156. 156 Poole, L.B., The basics of thiols and cysteines in redox biology and chemistry. Free Radic. Biol. Med. 80 (2015), 148–157.
157. 157 Bienert, G.P., et al. Membrane transport of hydrogen peroxide. Biochim. Biophys. Acta 1758 (2006), 994–1003.
158. 2, a necessary evil for cell signaling. Science 312 (2006), 1882–1883.
159. 159 Gilbert, H.F., Molecular and cellular aspects of thiol-disulfide exchange. Adv. Enzymol. Relat. Areas Mol. Biol. 63 (1990), 69–172.
160. 160 Le Moan, N., et al. The Saccharomyces cerevisiae proteome of oxidized protein thiols: contrasted functions for the thioredoxin and glutathione pathways. J. Biol. Chem. 281 (2006), 10420–10430.
161. 161 Chang, T.S., et al. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J. Biol. Chem. 279 (2004), 50994–51001.
162. 162 Nakashima, K., Regulatory sulfhydryl groups and activation by homocystine in liver fructose diphosphatase. Arch. Biochem. Biophys. 141 (1970), 579–587.
163. 163 Huang, Z., Inhibition of caspase-3 activity and activation by protein glutathionylation. Biochem. Pharmacol. 75 (2008), 2234–2244.
164. 164 Velu, C.S., et al. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 46 (2007), 7765–7780.
165. 165 Hill, B.G., et al. Methods for the determination and quantification of the reactive thiol proteome. Free Radic. Biol. Med. 47 (2009), 675–683.
166. 166 Ying, J., et al. Thiol oxidation in signaling and response to stress: detection and quantification of physiological and pathophysiological thiol modifications. Free Radic. Biol. Med. 43 (2007), 1099–1108.
167. 167 Leichert, L.I., Quantifying changes in the thiol redox proteome upon oxidative stress in vivo. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8197–8202.
168. 168 Eaton, P., et al. Glyceraldehyde phosphate dehydrogenase oxidation during cardiac ischemia and reperfusion. J. Mol. Cell Cardiol. 34 (2002), 1549–1560.
169. 169 Sullivan, D.M., Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry 39 (2000), 11121–11128.
170. 170 Brennan, J.P., et al. The utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. Mol. Cell. Proteomics 5 (2006), 215–225.
171. 171 Paulsen, C.E., Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 8 (2011), 57–64.
172. 172 Truong, T.H., Isotope-coded chemical reporter and acid-cleavable affinity reagents for monitoring protein sulfenic acids. Bioorg. Med. Chem. Lett. 21 (2011), 5015–5020.
173. 173 Yang, J., Site-specific mapping and quantification of protein S-sulphenylation in cells. Nat. Commun., 5, 2014, 4776.
174. 174 Seo, Y.H., Carroll, K.S., Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 16163–16168.
175. 175 Karisch, R., Global proteomic assessment of the classical protein-tyrosine phosphatome and “Redoxome”. Cell 146 (2011), 826–840.
176. 176 Cantrell, M.A., Kuo, C.J., Organoid modeling for cancer precision medicine. Genome Med., 7, 2015, 32.
177. 177 Yang, J., The expanding landscape of the thiol Redox proteome. Mol. Cell. Proteomics 15 (2016), 1–11.
178. 178 Ostergaard, H., Shedding light on disulfide bond formation: engineering a redox switch in green fluorescent protein. EMBO J. 20 (2001), 5853–5862.
179. 179 Dooley, C.T., Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators. J. Biol. Chem. 279 (2004), 22284–22293.
180. 180 Hanson, G.T., Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J. Biol. Chem. 279 (2004), 13044–13053.
181. 181 Meyer, A.J., Redox-sensitive GFP in Arabidopsis thaliana is a quantitative biosensor for the redox potential of the cellular glutathione redox buffer. Plant J. 52 (2007), 973–986.
182. 182 Ostergaard, H., et al. Monitoring disulfide bond formation in the eukaryotic cytosol. J. Cell Biol. 166 (2004), 337–345.
183. 183 Schwarzlander, M., Confocal imaging of glutathione redox potential in living plant cells. J. Microsc. 231 (2008), 299–316.
184. 184 Gutscher, M., et al. Real-time imaging of the intracellular glutathione redox potential. Nat. Methods 5 (2008), 553–559.
185. 2-scavenging peroxidases. J. Biol. Chem. 284 (2009), 31532–31540.
186. 2 receptor and redox-transducer in gene activation. Cell 111 (2002), 471–481.
187. 2 signaling. Nat. Chem. Biol. 11 (2015), 64–70.
188. 188 Albrecht, S.C., et al. In vivo mapping of hydrogen peroxide and oxidized glutathione reveals chemical and regional specificity of redox homeostasis. Cell Metab. 14 (2011), 819–829.
189. 189 Waypa, G.B., Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. Circ. Res. 106 (2010), 526–535.
190. 190 van Lith, M., Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. J. Cell Sci. 124 (2011), 2349–2356.
191. 191 Schnaubelt, D., Low glutathione regulates gene expression and the redox potentials of the nucleus and cytosol in Arabidopsis thaliana. Plant Cell Environ. 38 (2015), 266–279.
192. 192 Rosenwasser, S., Organelles contribute differentially to reactive oxygen species-related events during extended darkness. Plant Physiol. 156 (2011), 185–201.
193. 193 Hu, J., The redox environment in the mitochondrial intermembrane space is maintained separately from the cytosol and matrix. J. Biol. Chem. 283 (2008), 29126–29134.
194. 194 Kojer, K., Glutathione redox potential in the mitochondrial intermembrane space is linked to the cytosol and impacts the Mia40 redox state. EMBO J. 31 (2012), 3169–3182.
195. 195 Morgan, B., Multiple glutathione disulfide removal pathways mediate cytosolic redox homeostasis. Nat. Chem. Biol. 9 (2013), 119–125.
196. 196 Goldberg, J.A., Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat. Neurosci. 15 (2012), 1414–1421.
197. 197 Guzman, J.N., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468 (2010), 696–700.
198. 198 Wolf, A.M., Real-time monitoring of oxidative stress in live mouse skin. J. Invest. Dermatol. 134 (2014), 1701–1709.
199. 199 Breckwoldt, M.O., Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo. Nat. Med. 20 (2014), 555–560.
200. 200 Weigert, R., Imaging cell biology in live animals: ready for prime time. J. Cell Biol. 201 (2013), 969–979.
201. 201 Schwarzlander, M., Dissecting redox biology using fluorescent protein sensors. Antioxid. Redox Signal. 24 (2016), 680–712.
202. 202 Lin, S., Redox-based reagents for chemoselective methionine bioconjugation. Science 355:6325 (2017), 597–602.
203. 203 Smith, B.C., Marletta, M.A., Mechanisms of S-nitrosothiol formation and selectivity in nitric oxide signaling. Curr. Opin. Chem. Biol. 16:5–6 (2012), 498–506.
204. 204 Denninger, J.W., Marletta, M.A., Guanylate cyclase and the. NO/cGMP signaling pathway. Biochim. Biophys. Acta 1411:2–3 (1999), 334–350.
205. 205 Keshari, K.R., et al. Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc. Natl. Acad. Sci. U. S. A. 108:46 (2011), 18606–18611.
206. 206 Klomsiri, C., Cysteine-based redox switches in enzymes. Antioxid. Redox Signal. 14 (2011), 1065–1077.
207. 207 Bjelakovic, G., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. J. Am. Med. Assoc. 297 (2007), 842–857.
208. 208 Wang, J., Yi, J., Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 7 (2008), 1875–1884.
209. 209 Glasauer, A., Targeting SOD1 reduces experimental non-small-cell lung cancer. J. Clin. Invest. 124 (2014), 117–128.
210. 210 Raj, L., Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475 (2011), 231–234.
211. 211 Shaw, A.T., Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 8773–8778.
212. 212 Yun, J., Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350 (2015), 1391–1396.
213. 213 Rietjens, I.M., The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ. Toxicol. Pharmacol. 11 (2002), 321–333.
214. 214 Wright, M.E., et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330:15 (1994), 1029–1035.
215. 215 Cao, J., et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28:10 (2009), 1505–1517.